Sage Journals: Discover world-class research

Abstract

Objective:

To examine the association of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin complex 1 (m-TORC1) with preeclampsia (PE) and to explore their diagnostic significance in PE.

Methods:

A total of 153 singleton pregnant women were enrolled into our study, among which there were 97 patients with PE (mild PE [MPE]: n = 51; severe PE [SPE]: n = 46) and 56 healthy pregnant women (normal controls, NCs). Enzyme-linked immunosorbent assay (ELISA) and Western blot were used in this study. Moreover, a receiver–operating characteristic (ROC) curve was used to estimate the diagnostic significance.

Results:

After adjustment for confounding factors, at 24 to 28 gestational weeks, the serum levels of PI3K and m-TORC1 were both higher in the MPE and the SPE groups compared to those in the NC group (all P < .001). The serum levels of PI3K were positively correlated with the serum levels of m-TORC1 in both the NC and the PE groups at both 15 to 21 and 24 to 28 gestational weeks (both P < .001). Multivariable linear regression indicated that both PI3K and m-TORC1 were positively correlated with the systolic pressure (both P < .001). At 24 to 28 gestational weeks, there remained relatively high sensitivity and specificity when the serum levels of PI3K and m-TORC1 were used to diagnose PE (both P < .001). A Western blot assay found that there were significant differences in the PI3K and m-TORC1 protein expression among the 3 groups (all P < .001).

Conclusion:

The serum levels of PI3K and m-TORC1 might have the potential to diagnose PE, while PI3K and m-TORC1 fail to predict PE during early pregnancy.

Keywords

preeclampsia phosphoinositide 3-kinase mammalian target of rapamycin 1 diagnosis sensitivity specificity

Get full access to this article

View all access options for this article.

References

Ghulmiyyah

Sibai

. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. 2012;36(1):56–59.

Savaj

Vaziri

. An overview of recent advances in pathogenesis and diagnosis of preeclampsia. Iran J Kidney Dis. 2012;6(5):334–338.

Jeyabalan

. Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013;71(suppl 1):S18–S25.

Steegers

von Dadelszen

Duvekot

Pijnenborg

. Pre-eclampsia. Lancet. 2010;376(9741):631–644.

Laine

Ray

Bodnar

. Placental cadmium levels are associated with increased preeclampsia risk. PLoS One. 2015;10(9):e0139341.

Young

Levine

Karumanchi

. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173–192.

Foidart

Schaaps

Chantraine

Munaut

Lorquet

. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia – a step forward but not the definitive answer. J Reprod Immunol. 2009;82(2):106–111.

Hertig

Berkane

Lefevre

. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50(9):1702–1703.

Smith

Crossley

Aitken

. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109(6):1316–1324.

10.

Savvidou

Harland

Hingorani

Nicolaides

. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol. 2006;195(6):1668–1673.

11.

Park

Jeong

Kang

. Inhibition of the PI3K-Akt pathway suppresses sFlt1 expression in human placental hypoxia models in vitro. Placenta. 2010;31(7):621–629.

12.

Vanhaesebroeck

Stephens

Hawkins

. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195–203.

13.

Bartholomeusz

Gonzalez-Angulo

. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):121–130.

14.

Kawahara

Asthana

Kneteman

. m-TOR inhibitors: what role in liver transplantation?

J Hepatol. 2011;55(6):1441–1451.

15.

Hisamatsu

Mabuchi

Matsumoto

. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther. 2013;12(7):1367–1377.

16.

Slomovitz

Coleman

. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18(21):5856–5864.

17.

Miller

Rexer

Garrett

Arteaga

. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13(6):224.

18.

. World Medical Association publishes the Revised Declaration of Helsinki. Natl Med J India. 2014;27(1):56.

19.

Perucci

Gomes

Freitas

. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PLoS One. 2014;9(5):e97632.

20.

Rajakumar

Cerdeira

Rana

. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension. 2012;59(2):256–264.

21.

Naljayan

Karumanchi

. New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis. 2013;20(3):265–270.

22.

Liu

Zhao

Yan

Bao

Chen

. Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE(−/−) mice. PLoS One. 2012;7(5):e36237.

23.

Yasuda

. Hyaluronan inhibits Akt, leading to nuclear factor-kappaB down-regulation in lipopolysaccharide-stimulated U937 macrophages. J Pharmacol Sci. 2011;115(4):509–515.

24.

Appenzeller-Herzog

Hall

. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol. 2012;22(5):274–282.

25.

Kanninen

de Andrade Ramos

Jaffe

. Inhibition of autophagy by sera from pregnant women. Reprod Sci. 2013;20(11):1327–1331.

26.

Hsu

Kang

Rameseder

. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332(6035):1317–1322.

27.

Redman

Sargent

. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–1594.

28.

Chaft

Arcila

Paik

. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther. 2012;11(2):485–491.

29.

Porta

Paglino

Mosca

. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.

30.

Zhang

. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality. J Clin Pathol. 2015;68(7):522–528.

Diagnostic Significance of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Complex 1 in Preeclampsia